Dr. Bansal on Chemotherapeutic Approaches for Patients With Ovarian Cancer

Nisha Bansal, MD
Published: Monday, Jun 04, 2018



Nisha Bansal, MD, gynecologic oncologist, University of California, Los Angeles, discusses frontline chemotherapeutic approaches for patients with ovarian cancer.

The choice of chemotherapy will depend on several factors such as whether a patient has had optimal surgery with no evidence of visible disease, and whether they have undergone upfront surgery or received neoadjuvant chemotherapy. These variables will impact the treatment strategy, says Bansal. The traditional intravenous chemotherapy approach is carboplatin and taxol. It is an every 3-week regimen for a total of 6 cycles, says Bansal.

The other strategy for patients in the upfront setting who have been optimally cytoreduced is a combination of intravenous and intraperitoneal chemotherapy. That is a very attractive option, notes Bansal, because it delivers the chemotherapy directly into the peritoneal cavity. However, it comes with significant toxicity, so it may not be suitable for more elderly or medically infirm patients.

Another strategy would be a dose-dense regimen which seems to have a very good side effect profile. However, physicians do not yet know if it is useful in all patients.


Nisha Bansal, MD, gynecologic oncologist, University of California, Los Angeles, discusses frontline chemotherapeutic approaches for patients with ovarian cancer.

The choice of chemotherapy will depend on several factors such as whether a patient has had optimal surgery with no evidence of visible disease, and whether they have undergone upfront surgery or received neoadjuvant chemotherapy. These variables will impact the treatment strategy, says Bansal. The traditional intravenous chemotherapy approach is carboplatin and taxol. It is an every 3-week regimen for a total of 6 cycles, says Bansal.

The other strategy for patients in the upfront setting who have been optimally cytoreduced is a combination of intravenous and intraperitoneal chemotherapy. That is a very attractive option, notes Bansal, because it delivers the chemotherapy directly into the peritoneal cavity. However, it comes with significant toxicity, so it may not be suitable for more elderly or medically infirm patients.

Another strategy would be a dose-dense regimen which seems to have a very good side effect profile. However, physicians do not yet know if it is useful in all patients.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x